Glycemic screening and recurrent carbohydrate metabolism disorders with endocrine pathology

L.А. Lutsenko


The use of glycated hemoglobin for diabetes mellitus (DM) diagnosis is recommended by World Health Organization as of 2011. The level of glycated hemoglobin (HbA1c) ≥ 6.5 % is a diagnostic criterion for DM but HbA1c level of 6.0–6.4 % does not exclude diabetes mellitus diagnosis with hyperglycemia. Moreover, when diagnosing, evaluation of this criterion is a must, since decision about the nature and the scope of sugar-reducing therapy is based on the level of HbA1c. Counterregulatory hormones are glucagon, adre­nalin, somatotropin, glucocorticoids and thyroid hormones. Pathogenic mechanism of carbohydrate metabolism disorders with hypersecretion of counterregulatory hormones is caused by peripheral insulin resistance, decrease in insulin secretion, increase in gluconeogenesis and glycogenolysis in liver and increase in the absorption of intestinal glucose with insulin being the only hormone decreasing the blood glucose. So, the endocrine diseases (hypercorticism, acromegalia, pheochromocytoma, hyperparathyroidism and hyperthyroidism) with excessive secretion of counterregulatory hormones suggest the necessity of secondary diabetes diagnosis. Screening tests with quite high sensitivity and specificity have been developed for early diagnosis of endocrynopathies. Screening tests for hypercorticism diagnosis are dexamethasone (1 mg) suppression test, daily urinary cortisol excretion and nighttime salivary cortisol. Optimal test for screening acromegalia is considered to be insulin-like growth factor 1 which shows the secretion of somatotropic hormone during previous day and is not subject to significant fluctuations. One-time detection of increased insulin-like growth factor 1 level compared to referential values for specific sex and age is enough for confirmation of hypersomatotropinemia. Thyroid-stimulating hormone is recommended as a screening test for thyrotoxicosis diagnosis. When choosing this test, doctor should consider the parameter of analytical sensitivity of test system for thyroid-stimulating hormone. Screening for hyperparathyroidism is the detection of blood ionized calcium level. This examination is particularly relevant for patients from risk group for initial hyperparathyroidism — patients with gallstone disease, urolithiasis, stomach ulcer and/or duodenal ulcer, essential hypertension, etc. Free metanephrines of blood plasma and conjugated urine metanephrines are the screening tests for pheochromocytoma diagnosis. The level of methylated secondary catecholamines (metanephrines, normetanephrines) shows the daily tumor activity of pheochromocytoma. Thus, glycemic screening and endocrynopathies screening with hypersecretion of counterregulatory hormones should be conducted together. This will allow detecting secondary forms of diabetes mellitus and compensating glycemic state of the patient.


glycated hemoglobin; diabetes mellitus; hypercorticism; acromegalia


Tron'ko ND, Mankovsky BN. State program Diabetes mellitus. Doctor. 2003;1(5):9-12. (in Russian).

Dedov II, Mel'nichenko GA, Fadeev VV. Endokrinologiia: uchebnik [Endocrinology: a textbook]. Moscow: Meditsina; 2000. 631 p. (in Russian).

Setji TL, Brown AJ, Feinglos MN, et al. Gestational Diabetes Mellitus. Clinical Diabetes. 2005 Jan;23(1):17-24. doi: 10.2337/diaclin.23.1.17.

McDonald GW, Fisher GF, Burnham C. Reproducibility of the oral glucose tolerance test. Diabetes. 1965 Aug;14:473-80.

Gnudi L. Results of ACCORD and ADVANCE. Diabetes voice. 2009;54(1):29-32.

Likhonosova AP, Likhonosov NP, Kuznetsova OG. Glycosylated hemoglobin in the diagnosis of complications of diabetes mellitus. Novosti Meditsiny i Farmatsii. 2010;(325):128-130. (in Russian).

Handelsman Y, Bloomgarden ZT, Grunberger G, at al. American Association of clinical endocrinologists and American college of endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr;21 Suppl 1:1-87. doi: 10.4158/EP15672.GL.

Little RR, Rohlfing CL, Tennill AL, Connolly S, Hanson S. Effects of sample storage conditions on glycated hemoglobin measurement: evaluation of five different high performance lijauid chromatography methods. Diabetes Technol Ther. 2007 Feb;9(1):36-42. doi: 10.1089/dia.2006.0055.

Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care. 1999 Mar;22(3):394-8.

Petersen PH, Jørgensen LG, Brandslund I, De Fine Olivarius N, Stahl M. Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest Suppl. 2005;240:51-60. doi: 10.1080/00365510500236135.

Lenters-Shhestra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2010 Jan;56(1):44-52. doi: 10.1373/clinchem.2009.130641.

Kirilyuk ML. Diagnosis and treatment of hypophyseal Cushing’s syndrome. Mìžnarodnij endokrinologìčnij žurnal. 2014;(62):182-193. doi: 10.22141/2224-0721.6.62.2014.76950. (in Russian).

Coculescu M, Niculescu D, Lichiardopol R, Purice M. Insulin resistance and insulin secretion in non-diabetic acromegalic patients. Exp Clin Endocrinol Diabetes. 2007 May;115(5):308-16. doi: 10.1055/s-2007-961797.

Roelfsema F, Biermasz N, Pereira A, Romijn JA. Therapeutic options in the management of acromegaly: focus on lanreotide. Biologics. 2008 Sep;2(3):463-79.

Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004 Feb;25(1):102-152. doi: 10.1210/er.2002-0022.

Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca. 2000;27(1):27-31. (in German).

Nabarro J. Acromegaly. Clin Endocrinol (Oxf). 1987 Apr;26(4):481-512.

Procopio M, Boretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest. 2003;26(11):1136-1142. doi: 10.1007/BF03345264.

Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003 Dec;88(12):5808-13. doi: 10.1210/jc.2003-030254.

Rosario P. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary. 2011 Sep;14(3):217-21. doi: 10.1007/s11102-010-0281-0.

Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40. doi: 10.1210/jc.2008-0125.

Belaya ZE, Il'in AV, Mel'nichenko GA, et al. Automated electrohemiluminiscent method of determination of cortisol in saliva for diagnostics of endogenous hypercorticism in patients with obesity. Obesity and Metabolism. 2011;8(2):56-63. doi: 10.14341/2071-8713-4954. (in Russian).

Dreval AV, Komerdus IV, Murzina AV, et al. The prevalence of subclinical hypercorticism among the patients presenting with type 2 diabetes mellitus and alimentary obesity. Problemi Endokrinologii. 2014;60(1):9-17. doi: 10.14341/probl20146019-17. (in Russian).

Karachentsev IuI, Khizhniak OO, Mikitiuk MR, Kutsyn VN. Akromegaliia i gigantism [Acromegaly and gigantism]. Kyiv: Start-98; 2010. 132 p. (in Russian).

Jonklaas J, Kahric-Janicic N, Soldin O, Soldin SJ. Correlations of free thyroid hormones measured by tandem mass spectrometry and immunoassay with thyroid-stimulating hormone across 4 patient populations. Clin Chem. 2009 Jul;55(7):1380-8. doi: 10.1373/clinchem.2008.118752.

Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2018


 Яндекс.МетрикаSeo анализ сайта Рейтинг